Tango Therapeutics, Inc. (TNGX) Form 8-K — Jun 23, 2026
Tango Therapeutics appointed Robert Azelby to its Board of Directors, increasing the total number of directors to seven. Mr. Azelby will serve as a Class II director with a term expiring at the 2029 annual meeting of stockholders. Mr.
Key figures
- Board Size
- 7
- Rsu Awarded
- 5740
- Options Awarded
- 35910
- Annual Retainer Board
- 45000
- Option Exercise Price
- 27.97
- Annual Retainer NCGCommittee
- 5000
- Annual Retainer Comp Committee
- 7500
Price after filing
1 day: +2.6%7 days: +10.1%30 days: -1.0%
Close on the filing date to close N calendar days later (from $28.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.